A group of major pharmaceutical companies will share pooled data from failed clinical trials in an attempt to figure out what is going wrong in the studies and what can be done to improve drug development.
The data will be available to all the participating drug makers, as well as outside researchers with a valid scientific question, Dr. Cantillon said.